Positive progress for the immunosuppressant monitoring trial

Our Nanodem study to monitor immunosuppressant drugs that prevent rejection in transplant patients, is proceeding well. We now have 12 patients completed and will continue in the next 3 weeks with additional subjects.  In addition, Probe has been invited Munich to join a consortium involving Munich as well as other German, Austrian, Danish, Spanish and Greek partners to submit an application for EU funding to optimized antibiotics dosing in severe illness.